Limonene
1. Identity: Chemical and Botanical Profile
1.1 Chemical Classification and Names
Limonene is a colorless liquid aliphatic hydrocarbon classified as a cyclic monoterpene, and is the major component in the fragrance and essential oil of citrus fruit peels, taking its name from Italian limone ("lemon"). Its IUPAC name is 1-methyl-4-(1-methylethenyl)-cyclohexene. It is also known as 4-isopropenyl-1-methylcyclohexene and p-Menth-1,8-diene. It has a chemical formula of C10H16, a molecular weight of 136.2, and contains 88.1% carbon and 11.8% hydrogen by weight.
Limonene is a chiral molecule, and most biological sources produce just one enantiomer. The (+)-isomer, d-limonene, which is the (R)-enantiomer, occurs more commonly in nature in citrus fruit peels — the principal commercial source — from which it is obtained commercially by two primary methods: centrifugal separation and steam distillation. The less common (−)-isomer, l-limonene, which is the (S)-enantiomer, has a piny, turpentine-like odour, and is found in the edible parts of such plants as caraway, dill, and bergamot orange plants. Racemic limonene is known as dipentene.
Limonene also comes in the form of d,l-limonene (CAS 138-86-3), commonly known as dipentene; it is a mixture of the two isomers. The d-isomer (CAS 5989-27-5) is the predominant form studied and used in dietary supplement contexts, and is almost exclusively referred to when the term "d-limonene" or simply "limonene" is used in supplement, food, and clinical literature.
1.2 Natural Sources
Limonene is widely distributed among citrus and other plant species. It has been reported in more than 300 essential oils, at concentrations up to 90–95%, and at lesser — although still appreciable — concentrations in foods (e.g., 800 mg/L in non-alcoholic beverages, 3000 mg/kg in chewing gum). The essential oil from citrus plants may contain 70–98% of (+)-limonene as a major constituent.
It is a major constituent of oil of citrus rind, dill oil, and oil of cumin, neroli, bergamot, and caraway. The d-form comprises 98–100% of the limonene in most citrus oils (family Rutaceae), whereas that in oil of citronella and oil of lemongrass (family Gramineae) is 96–100% l-limonene. In the extraction of citrus juices, d-limonene is obtained as a by-product; l-limonene is present in pine needles and cones; dl-limonene, or dipentene, the mixture of equal amounts of the l- and d-isomers, is a component of turpentine.
Limonene is also the natural precursor for the biosynthesis of menthol and carvone in peppermint and spearmint, respectively. A significant amount of limonene has also been detected in the headspace of fungal cultures such as Aspergillus fumigatus and Trichoderma viride.
1.3 Biosynthesis
In nature, limonene is formed from geranyl pyrophosphate via cyclization of a neryl carbocation or its equivalent. The final step involves loss of a proton from the cation to form the alkene. Limonene is a well-known cyclic monoterpene that is synthesized directly from GPP (geranyl diphosphate) by an enzyme limonene synthase.
1.4 Commercial Production and Grades
Some limonene is prepared by extraction from plants of the mint family; a large quantity is obtained from citrus oils, which are typically 80–90% limonene; and some is obtained from pine oil. d-Limonene can be obtained by steam extraction of citrus peels of orange, lemon, lime, grapefruit, and bergamot. Some extractions can contain as high as 90% d-limonene; however, to produce technical grades of higher purity (i.e., greater than about 95%), distillation of the oils is required.
The estimated worldwide production is over 70,000 tonnes per year, and demand is constantly increasing. For nearly 50 years, d-limonene and orange oil/essence oil (95% d-limonene) have been used widely as flavour and fragrance additives in perfume, soap, food, and beverages. d-Limonene has been used in non-alcoholic beverages, ice cream and ices, sweets, baked goods, gelatins and puddings, and chewing gum.
1.5 Common Supplement Forms and Preparations
Limonene is available in several commercial supplement and non-supplement preparations:
- Oral soft-gel capsules containing food-grade d-limonene oil (typically standardized to ≥97% d-limonene).
- Citrus essential oils (e.g., orange, lemon, grapefruit peel oil), of which limonene is the predominant component.
- Food-additive grade liquid, incorporated into flavored beverages, confectionery, baked goods, and chewing gum.
- It is also used as a chemical intermediate in the production of l-carvone, in terpene resin manufacture as a wetting and dispersing agent, and in the preparation of sulfurized terpene lubricating oil additives.
2. Traditional and Historical Use
Limonene has a history of use in medicine, food, and perfume. While the isolated compound was not identified and named until the mid-19th century, the plant materials richest in limonene — citrus peels — have been employed across multiple traditions for millennia.
2.1 Traditional Chinese Medicine
The citrus plant is the general term for Citrus, Fortunella, and Poncirus, which includes oranges, tangerines, lemons, grapefruits, and citrons. Not only does it contain a variety of delicious fruits, but it is also an important part of traditional Chinese medicine. Citrus plant peels are rich in essential oils, the primary active component of which is limonene. Dried citrus peel preparations — including Chenpi (aged tangerine peel, Citrus reticulata) and Qingpi (unripe peel) — have been used for centuries in Chinese herbal medicine as qi-regulating, digestive, and phlegm-resolving agents.
2.2 Food Cultures and Culinary Traditions
Traditional food cultures, like Mediterranean diets, have long used citrus zest in olive oil and marinades — unknowingly leveraging limonene's bioactivity. Traditionally, (+)-limonene is used as a flavoring compound in citrus-flavored products such as soft drinks and candy, and as a fragrance ingredient in household cleaning products and perfumes.
2.3 Modern Historical Trajectory
The story of limonene in modern science kicked off in the mid-19th century when chemists distilled citrus oils and characterized the main constituents. By the 1950s, researchers identified limonene's structure and noted its fragrant role. In the 1970s–1980s, interest surged around its insect-repelling properties and later its potential anti-cancer signals in rodent models.
Consumption of d-limonene has been estimated to be 0.2–2 mg/kg body weight per day through normal dietary exposure — the level at which humans have been naturally consuming the compound for centuries through citrus fruits and citrus-flavored food products.
3. Key Constituents, Metabolites, and Mechanisms of Action
3.1 Primary Compound
The bioactive entity in most supplement and clinical research contexts is d-limonene itself. However, much of its pharmacological activity is also attributable to its metabolic products formed during hepatic processing.
3.2 Metabolic Pathways and Principal Metabolites
The principal metabolites of limonene are (+)- and (−)-trans-carveol, a product of 6-hydroxylation, and (+)- and (−)-perillyl alcohol, a product of 7-hydroxylation by CYP2C9 and CYP2C19 cytochromes in human liver microsomes. Perillyl alcohol is itself pharmacologically active and has been studied independently as an anticancer agent. d-Limonene is converted to perillyl alcohol by hydroxylation through enzymes belonging to the superfamily of cytochrome P450 proteins.
The chemopreventive activity of limonene during initiation can be attributed to the induction of phase I and phase II enzymes, with resulting carcinogen detoxification. The chemopreventive activity of limonene during promotion/progression may be due in part to inhibition of the posttranslational isoprenylation of growth-controlling small G proteins, such as p21ras.
3.3 Anti-Inflammatory Mechanisms
Research demonstrates that limonene action focuses on the Myd88-dependent pathway of the inflammatory cascade and produces a strong anti-inflammatory effect, targeting the TLR4/AP-1/NF-κB axis. One of the critical regulators of the oxidative stress response is the transcription factor Nrf2. Studies have revealed that limonene at 200 mg/kg significantly amplified Nrf2 gene expression in jejunal tissues.
In experimental models of ulcerative colitis, disease activity and colonic mucosa damage were significantly reduced by the anti-inflammatory effects of D-limonene via suppression of matrix metalloproteinase (MMP)-2 and -9 gene expression. A decrease in prostaglandin E2 (PGE2) production, transforming growth factor-β (TGF-β) gene expression, and an increase in phosphorylated ERK1/2 expression levels were observed in D-limonene-treated animals. D-limonene reduced MMP-2 and -9 mRNA expression levels via regulation of the iNOS, COX-2, PGE2, TGF-β, and ERK1/2 signaling pathways.
3.4 Antioxidant Mechanisms
D-limonene upregulates levels of the antioxidant enzymes superoxide dismutase 1 (SOD1) and heme oxygenase 1 (HO-1) and the anti-apoptotic protein Bcl-2, while reducing the number of TUNEL-positive cells. D-limonene has a neuroprotective effect mediated by the activation of the AMPKα signaling pathway, and hence inhibits ROS and inflammatory factors.
3.5 Anticancer Mechanisms
Research has shown increased levels of p53, Bax, and caspase-3 during D-limonene treatment, while Bcl-2 levels decreased, suggesting the mitochondria-mediated intrinsic death pathway plays a crucial role in D-limonene-induced cancer cell death. The compound's therapeutic effects are mediated through multiple mechanisms, including modulation of oxidative stress, induction of apoptosis, and regulation of inflammatory responses.
3.6 Metabolic and Lipid Mechanisms
Reporter assay and gene expression analysis found that d-limonene activates peroxisome proliferator-activated receptor (PPAR)-α signaling and inhibits liver X receptor (LXR) activity, pathways centrally involved in lipid metabolism and adipogenesis. At effective doses, d-limonene in adipocyte models and high-calorie diet-induced obese rats can activate the AMPK signaling pathway. The activated AMPK regulated the mRNA expression related to adipogenesis (PPARγ, C/EBPα, FABP4), lipogenesis (SREBP-1c, ACC, FAS), and lipolysis (ATGL, HSL) to inhibit obesity.
3.7 Neurological and Neurotransmitter Mechanisms
d-Limonene and its metabolites have been shown useful in alleviating depression and anxiety, with antidepressant activities shown to mediate GABAergic, monoaminergic, and neurotrophic mechanisms, as evidenced by the inhibition of hypothalamic-pituitary-adrenal axis hyperactivity and the reduction of monoamine neurotransmitters. Flumazenil administration inverted anxiolytic-like effects of d-limonene in animal models, pinpointing an involvement of benzodiazepine-type receptors in facilitating those effects.
4. Scientific Evidence by Area of Use
4.1 Cancer: Chemopreventive and Antitumor Activity
Preclinical Evidence
The naturally occurring monoterpene d-limonene has chemopreventive and chemotherapeutic activity against many rodent solid tumor types. The multiple antitumorigenic effects of limonene are attainable at a high therapeutic ratio, suggesting that limonene and related monoterpenes may be efficacious in the chemoprevention and chemotherapy of human malignancies. The complete regression of mammary carcinomas by limonene in animal models appears to involve tissue redifferentiation.
In cell-based models of colorectal cancer, D-limonene exhibits concentration-dependent antiproliferative activity against colorectal cancer cells. The compound's therapeutic effects are mediated through multiple mechanisms, including modulation of oxidative stress, induction of apoptosis, and regulation of inflammatory responses.
Human Clinical Evidence
D-limonene is a natural monoterpene with pronounced chemotherapeutic activity and minimal toxicity in preclinical studies. A phase I clinical trial assessed toxicity, the maximum tolerated dose (MTD), and pharmacokinetics in patients with advanced cancer, followed by a limited phase II evaluation in breast cancer.
In this Cancer Research Campaign study, a group of 32 patients with refractory solid tumors completed 99 courses of D-limonene 0.5 to 12 g/m² per day administered orally in 21-day cycles. Pharmacokinetics were analyzed by liquid chromatography-mass spectrometry. Ten additional breast cancer patients received 15 cycles of D-limonene at 8 g/m² per day. The MTD was 8 g/m² per day; nausea, vomiting, and diarrhea were dose-limiting. One partial response in a breast cancer patient on 8 g/m² per day was maintained for 11 months; three patients with colorectal carcinoma had prolonged stable disease. D-Limonene was well tolerated in cancer patients at doses which may have clinical activity; the favorable toxicity profile supported further clinical evaluation.
A subsequent clinical study investigated breast tissue disposition. One study (n = 43 participants) showed d-limonene concentrated in breast tissue (mean 41.3 μg/g tissue) and reduction in tumor cyclin D1 expression, which is associated with tumor proliferation arrest. This study did not show meaningful change in serum biomarkers associated with breast cancer, except for a statistically significant increase in insulin-like growth factor-1 (IGF-I) levels. While elevation of IGF-I is associated with increased cancer risk, the clinical implication of this study remains uncertain given its short duration.
Specifically, limonene intervention resulted in a 22% reduction in cyclin D1 expression (P=0.002) in tumor tissue but minimal changes in tissue Ki67 and cleaved caspase 3 expression. No significant changes in serum leptin, adiponectin, TGF-β1, IGFBP-3, and IL-6 levels were observed following limonene.
Scoping Review: Breast Cancer Evidence
A scoping review aimed to explore the breadth and depth of existing evidence on the effect of d-limonene and its derivatives on breast cancer in human subjects. The review yielded five eligible studies with a total of 133 participants, evaluating the chemotherapeutic properties of d-limonene (n = 2 trials; 85 participants) and perillyl alcohol (n = 3 trials; 48 participants). The number of articles resulting from the search was noticeably small, demonstrating the dearth of evidence available on the effect of d-limonene on breast cancer in human subjects. All studies included were early-phase (1 and 2) clinical trials evaluating safety and efficacy.
Trials evaluating the effect of d-limonene (n = 2) showed it was well tolerated in subjects. Trials with perillyl alcohol (n = 3) showed low tolerance and no effect on breast cancer. Clinical development of monoterpenes has focused on a hydroxylated analog of limonene, perillyl alcohol. Multiple early-phase trials have been conducted with perillyl alcohol in advanced cancer patients, with a few reported cases of disease stabilization. It was concluded that clinical antitumor activity of perillyl alcohol is not likely to occur at safe doses.
Evidence strength (oncology): Preliminary. Human evidence consists exclusively of early-phase trials (Phase I and II), small sample sizes, and a single scoping review. No randomized controlled trials with efficacy endpoints exist for d-limonene as a cancer therapeutic. Preclinical data are robust but do not translate directly to clinical efficacy conclusions.
4.2 Gastrointestinal Health: Gallstone Dissolution
Being a solvent of cholesterol, d-limonene has been used clinically to dissolve cholesterol-containing gallstones. The most robust human clinical evidence for d-limonene in any therapeutic context relates to its use as a direct biliary instillate for gallstone dissolution.
Complete dissolution of gallstones was observed in 96 cases (48%), partial dissolution in 29 (14.5%), and complete dissolution with hexametaphosphate (a chelating agent known to be a good solvent for the dissolution of bilirubin calcium stones) in the remaining 16%. This evidence, derived from a Japanese clinical series, involved direct instillation of d-limonene preparation into the biliary system.
The solubility and dissolving velocity of d-limonene is better than those of sodium cholate and heparin, but complete dissolution in the bile duct was seldomly observed during clinical administration. Furthermore, d-limonene is noted to be stimulative to patients and requires a special catheter insoluble in d-limonene.
Evidence strength (gallstones): Moderate for direct biliary instillation. Controlled case series in Japanese surgical patients documented significant dissolution rates. However, this route of administration is a clinical procedure, not oral supplementation, and the evidence does not extend to gallstone dissolution by oral intake.
4.3 Gastrointestinal Health: Acid Reflux and GERD
D-limonene is also useful for relieving occasional heartburn and gastroesophageal reflux disease (GERD). Because of its gastric acid neutralizing effect and its support of normal peristalsis, it has also been used for this purpose. The proposed mechanism involves d-limonene's lower density relative to water, allowing it to coat the esophageal lining and neutralize acid on contact.
There are few high-quality studies proving that d-limonene works in humans for GERD. So far, the main evidence supporting its use is anecdotal. A 2019 animal study demonstrated the protective effects of d-limonene on the gastrointestinal system in rats; the authors suggested that d-limonene produces its beneficial effect by increasing mucus production.
Evidence strength (GERD/heartburn): Very weak for oral supplementation. Evidence in humans is largely anecdotal. Animal data and mechanistic plausibility exist but are insufficient to support clinical claims.
4.4 Metabolic Health: Obesity, Lipids, and Blood Glucose
The metabolic effects of d-limonene have been investigated predominantly in preclinical models. D-limonene has been reported to alleviate fatty liver induced by a high-fat diet. In preventive treatment experiments, d-limonene decreased the size of white and brown adipocytes, lowered serum triglyceride (TG) and fasting blood glucose levels, and prevented liver lipid accumulations in high-fat diet-fed mice. In the therapeutic treatment, d-limonene reduced serum TG, low-density lipoprotein cholesterol (LDL-c), and fasting blood glucose levels and glucose tolerance, and increased serum high-density lipoprotein cholesterol (HDL-c) in obese mice.
The anti-obesity metabolic pathway showed that d-limonene at doses above 154 mg/kg in high-calorie diet-induced obese rats could activate the AMPK signaling pathway. The activated AMPK regulated the mRNA expression related to adipogenesis (PPARγ, C/EBPα, FABP4), lipogenesis (SREBP-1c, ACC, FAS), and lipolysis (ATGL, HSL) to inhibit obesity.
These data suggest that the intake of d-limonene may benefit patients with dyslipidemia and hyperglycemia and represent it as a potential dietary supplement for preventing and ameliorating metabolic disorders. However, these conclusions derive from animal studies.
Evidence strength (metabolic health): Preliminary; entirely preclinical (animal and cell models). No human clinical trials have directly investigated d-limonene's effects on obesity, blood glucose, or blood lipids in humans.
4.5 Neurological Health: Anxiety, Depression, and Neuroprotection
There is notable interest in investigating the pharmacological effects of limonene in various chronic diseases due to its mitigating effect on oxidative stress and inflammation and regulating apoptotic cell death. There are several available studies demonstrating the neuroprotective role of limonene in neurodegenerative diseases, including Alzheimer's disease, multiple sclerosis, epilepsy, anxiety, and stroke.
Studies report that limonene attenuates anxiety in the elevated plus maze (EPM) model of anxiety in mice. The effects of limonene were reported at two concentrations of 0.5% and 1.0%, and showed that limonene improved all parameters assessed in the elevated plus maze test.
The effects of D-limonene on male rats subjected to 21 days of restraint stress were investigated. D-limonene reduced depression-like behavior in both the sucrose preference test and the open-field test. This 2024 study published in the European Journal of Neuroscience was conducted entirely in animal subjects, and the authors noted limitations including the exclusive use of male rats.
d-Limonene, a monoterpene shown to reduce inflammatory parameters in several pre-clinical and clinical models, could develop an anti-stress action by altering ortho/parasympathetic parameters as well as central neurotransmitter functions. A rat functional observational battery was performed, submitting animals to non-pathological stress. d-Limonene or its metabolite perillyl alcohol (POH) were administered per os at a dose of 10 mg/kg.
A published review emphasizes the neuroprotective potential of limonene against neurodegenerative and other neuroinflammatory diseases. The available data are indicative of the nutritional use of products containing limonene and may direct future preclinical and clinical studies for the development of limonene as an alternative or complementary phytomedicine.
Evidence strength (neuroprotection/mood): Preliminary and largely preclinical (animal models). No controlled human clinical trials have been conducted on d-limonene for anxiety, depression, or any neurodegenerative disease. All mechanistic and behavioral data come from rodent studies.
4.6 Anti-Inflammatory Activity
Limonene's potent anti-inflammatory activity mediates multiple pathways and mediators of inflammation, including inhibition of pro-inflammatory cytokines, chemokines, and adhesion molecules, along with the suppression of macrophage infiltration and neutrophil-endothelial cell interaction. These effects have been characterized in animal models but not yet confirmed in controlled human trials.
The therapeutic effects of limonene have been extensively studied, proving anti-inflammatory, antioxidant, antinociceptive, anticancer, antidiabetic, antihyperalgesic, antiviral, and gastroprotective effects, among other beneficial effects, though this evidence base remains primarily preclinical.
Evidence strength (anti-inflammatory): Mechanistic evidence in animals and cell models is strong and well-characterized. Human clinical evidence for anti-inflammatory endpoints is absent.
5. Body Systems Associated with Limonene
Limonene's biological versatility spans antioxidant, anti-inflammatory, antitumor, antidiabetic, neuroprotective, and gastroprotective domains. The following body systems are associated with its studied activities:
- Gastrointestinal system: Gallstone dissolution (direct instillation), gastric acid neutralization, mucosal protection, and gut barrier integrity (animal models).
- Hepatic system: Reduction of liver lipid accumulation in high-fat diet models; activation of PPAR-α signaling; modulation of phase I and II detoxification enzymes.
- Metabolic/Endocrine system: Lipid lowering, blood glucose modulation, and AMPK activation observed in animal models.
- Nervous system: Anxiolytic-like and antidepressant-like effects mediated through GABAergic and monoaminergic systems in animal models; potential neuroprotection in Alzheimer's disease and stroke models.
- Oncology: Inhibition of cancer cell proliferation via apoptosis induction, cyclin D1 reduction, and inhibition of isoprenylation of ras oncoproteins; early-phase human data in breast and colorectal cancer.
- Immune system: Immunomodulatory activity; inhibition of NF-κB and inflammatory cytokines.
- Integumentary system (skin): As a fragrance and topical ingredient, with noted sensitization risk upon oxidation.
6. Dosage Forms and Dosages Reported in Studies
The following dosages are drawn directly from cited clinical and research sources and are reported descriptively, not as recommendations:
- Phase I/II Cancer Trial (oral): 32 patients with refractory solid tumors completed 99 courses of D-limonene 0.5 to 12 g/m² per day, administered orally in 21-day cycles. The maximum tolerated dose (MTD) was 8 g/m² per day; dose-limiting toxicities were nausea, vomiting, and diarrhea.
- Perillyl alcohol (Phase I dose escalation for breast cancer): Dose escalation studies ranged from 800 to 2400 mg/m² per dose, with an MTD of 1200 mg/m² per dose.
- Animal anti-inflammatory studies: Limonene at 200 mg/kg significantly amplified Nrf2 gene expression in jejunal tissues. Treatment was used in 2 doses (100 mg/kg and 200 mg/kg) for 5 consecutive days prior to LPS challenge in mice.
- Anti-stress rat study: d-Limonene or its metabolite perillyl alcohol were administered per os at a dose of 10 mg/kg.
- Anti-obesity rat study: 154 mg/kg body weight was identified as an optimal effective dose for anti-obesity effects induced by a high-calorie diet.
- Gallstone dissolution (biliary instillation): 5 mL of D-limonene preparation was gradually introduced into a CHR-tube for biliary infusion, continuing for several weeks.
It should be noted that commercially available oral d-limonene supplement capsules are typically marketed at 1,000 mg per soft-gel, a dose substantially below those used in the cancer Phase I trials (which were in gram-per-m² ranges based on body surface area).
7. Safety, Toxicology, and Regulatory Status
7.1 Regulatory Classification
The FDA lists limonene as Generally Recognized as Safe (GRAS) as a food additive or flavoring and a fragrance additive (21 CFR 182.60). The EFSA (European Food Safety Authority) has evaluated limonene and its enantiomers, concluding that they are safe for use as flavoring agents at levels typically found in food products.
7.2 General Toxicology
Limonene is of relatively low acute toxicity taken orally. In preclinical and clinical studies, d-limonene has demonstrated low acute toxicity. Oral LDâ‚…â‚€ values in rodents exceed 5,000 mg/kg, placing it in the low-toxicity category.
Although initial carcinogenicity results showed d-limonene increased the incidence of renal tubular tumors in male rats, female rats and mice in both genders showed no evidence of any tumor. Subsequent studies have determined how these tumors occur and established that d-limonene does not pose a mutagenic, carcinogenic, or nephrotoxic risk to humans. In humans, d-limonene has demonstrated low toxicity after single and repeated dosing for up to one year.
A subchronic study by the National Toxicology Program (NTP) using rats and mice resulted in decreased body weights, kidney disease, and mortality at the highest dose tested. A chronic toxicity study by NTP using rats resulted in decreased body weight, kidney disease, and kidney tumors, which occurred due to a species-specific mechanism. This species-specific mechanism has been attributed to the accumulation of alpha-2u-globulin protein, which is unique to male rats and does not occur in humans.
7.3 Dose-Dependent Adverse Effects in Clinical Use
In the Phase I cancer trial using high oral doses, nausea, vomiting, and diarrhea were dose-limiting at 8 g/m² per day and above. These gastrointestinal effects appear to be dose-dependent and are not observed at typical dietary or supplement doses.
7.4 Skin Sensitization and Contact Allergy
Limonene can potentially cause skin sensitization, which is why its use is restricted in fragrances. The International Fragrance Association (IFRA) has established a standard that restricts the use of limonene due to this potential for sensitization. While limonene is GRAS by the FDA for use as a flavoring agent, it is included on the list of "allergenic" substances in Europe.
The European Union's Regulation 1223/2009 requires that any of 26 substances recognized as allergenic be indicated on the ingredients list for cosmetics products supplied to EU markets. This includes limonene.
Critically, the sensitizing risk is primarily associated with oxidized limonene rather than fresh limonene. Unoxidized limonene is a mild irritant, but its oxidized form, created upon exposure to air, is a potent skin allergen, causing redness and inflammation. Oxidized limonene is a common cause of allergic contact dermatitis, especially in individuals with pre-existing conditions like eczema. Hydroperoxides of limonene and linalool are potent sensitizers and represent the clinically relevant allergenic fraction. Not only oxidized R-(+)- but also S-(−)-limonene is a common cause of contact allergy in dermatitis patients in Europe.
The age of a product, its packaging, and its storage conditions are therefore critical factors in determining its risk profile for users with sensitive skin.
7.5 Drug Interactions: CYP450 Metabolism
The principal metabolites of limonene are formed by CYP2C9 and CYP2C19 cytochromes in human liver microsomes. Because d-limonene is metabolized by CYP2C9 and CYP2C19, and because these enzymes are involved in the metabolism of numerous pharmaceutical drugs (including warfarin, phenytoin, and certain anti-diabetic agents via CYP2C9; and proton pump inhibitors and certain antidepressants via CYP2C19), competitive interaction is theoretically possible at high doses. Potential CYP2C9 drug interactions may alter medication metabolism. However, clinically significant interactions at supplemental doses have not been formally characterized in controlled pharmacokinetic drug-interaction studies.
7.6 Respiratory Considerations
Inhalation of high concentrations of limonene vapor or mist can cause respiratory tract irritation. This is more common in industrial settings or with high-concentration essential oil use.
8. Summary of Evidence Quality
Across its many proposed areas of benefit, the evidence base for d-limonene varies substantially by indication:
- Gallstone dissolution (biliary instillation): Moderate human clinical evidence from case series, limited by non-randomized design and a specific, procedurally administered route.
- Cancer (early-phase trials): Phase I/II human data demonstrate tolerability and early signals of bioactivity (cyclin D1 reduction, tumor tissue accumulation). Efficacy has not been established in randomized trials. Evidence is early-phase and preliminary.
- Anti-inflammatory, antioxidant, metabolic, and neuroprotective effects: Predominantly animal and in vitro evidence. Mechanisms are well-characterized in preclinical models but have not been validated in human clinical trials.
- GERD/heartburn: Anecdotal in humans; one preclinical (animal) study. Evidence is insufficient to support clinical claims.
- Safety profile: Well-characterized. GRAS status, very low oral toxicity, known skin sensitization risk from oxidized limonene, and dose-dependent GI effects at high pharmacological doses are all well-documented.
References
Go back